Comparative Pharmacology
Head-to-head clinical analysis: SOLODYN versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOLODYN versus TETRACYN.
SOLODYN vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Solodyn (minocycline hydrochloride) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
1 mg/kg orally once daily as extended-release tablets; not to exceed 100 mg/day. Alternatively, 1 mg/kg orally once daily as immediate-release tablets; not to exceed 100 mg/day.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
Terminal elimination half-life: 11-22 hours (mean ~16 hours). Clinically, steady-state reached in 3-4 days; half-life prolonged in renal impairment.
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Primarily renal (40-70% unchanged) via glomerular filtration; significant biliary/fecal (20-30%) as unchanged drug and metabolites. Enterohepatic recirculation occurs.
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic